William Blair on Verve Therapeutics (VERV): 'Heart-2 First Look: Reads as a Clear Win With Clean VERVE-102 Safety'
Tweet Send to a Friend
William Blair analyst Raju Prasad reiterated an Outperform rating and {REMOVEPT} price target on Verve Therapeutics (NASDAQ: VERV)The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
